Roche gets a leg up in the anti-TIGIT race with first breakthrough designation for PhII winner tiragolumab

In the race to usher in a next generation of immunotherapies, Roche’s Genentech has emerged from the pack, nabbing the first breakthrough designation for an anti-TIGIT drug. The pharma giant’s tiragolumab plus Tecentriq landed a spot in the FDA’s expedited review program for the first-line treatment of metastatic non-small cell…

Click to view original post